20 November - Novo Nordisk and UNICEF announced a new partnership today to help prevent childhood overweight and obesity worldwide with an initial focus on interventions in Latin America and the Caribbean.
Under this partnership, the United Nations children’s agency and the global healthcare company will combine efforts to enhance knowledge and awareness on how to prevent overweight and obesity and address their root causes. The partnership will initially cover a period of three years.
“There is no doubt that childhood overweight and obesity is a public health crisis that requires immediate attention. Childhood overweight and obesity is more than an individual choice, this is everybody’s business. Together with UNICEF, we hope to help millions of children lead healthy lives and at the same time ease the burden of obesity to society,” says Novo Nordisk President and CEO Lars Fruergaard Jørgensen.
18 November - Novo Nordisk and Dicerna today announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC™ RNAi platform technology. The collaboration plans to explore more than 30 liver cell targets and may deliver multiple clinical candidates for disorders including chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases. Dicerna will conduct and fund discovery and preclinical development to clinical candidate selection for each liver cell target, and Novo Nordisk will be responsible for all further development.
“Through this important collaboration with Dicerna, we gain access to an innovative technology and deep expertise in RNA interference,” said Marcus Schindler, senior vice president of Global Drug Discovery in Novo Nordisk. “Dicerna is the ideal partner to discover and develop molecules for targets that may yield multiple potential treatments across disease areas such as diabetes, obesity, cardiovascular and NASH. We will work closely together to unlock the true potential of treating a range of diseases using RNAi therapies, for the benefit of patients.”
Bagsværd, Denmark, 1 November 2019 - Sales increased by 9% in Danish kroner and by 5% at CER to DKK 89.6 billion. Sales in International Operations increased by 13% in Danish kroner (11% at CER), driven by growth in all regions.
Lars Fruergaard Jørgensen, president and CEO: "We're very satisfied with the sales growth for the first nine months of 2019, which was driven by all regions in International Operations and growth across our therapy areas Diabetes, Obesity and Biopharmaceuticals. During the third quarter of 2019, we have reached two very important milestones: the US FDA approval of Rybelsus® and the blockbuster status of Ozempic® following the successful launch in the USA; two major events that emphasise the strength of our current and future GLP-1 franchise.”
China is facing a diabetes crisis, with more than one in 10 people living with the condition. The Chinese government, however, is fighting back with ambitious plans to deploy the latest technology to bring the epidemic under control, as Novo Nordisk CEO Lars Fruergaard Jørgensen saw for himself during a recent visit.
What if medicines injected by millions could be delivered in tablets?
After almost 100 years of delivering injectable therapies, Novo
Nordisk’s R&D team is finding answers to this enduring question.
Chief Science Officer Mads Krogsgaard Thomsen is leading the way and
he reflects on the magnitude of the scientific challenge and the
progress made in his laboratories.
Novo Nordisk intends to achieve the target to use only renewable electricity in
its global production facilities by 2020. The announcement on 30
April followed a new investment in a 672-acre solar panel
installation, roughly the size of 500 football fields, in North
Carolina, US, which will provide power to Novo Nordisk’s entire US
operations from early 2020. Novo Nordisk is the first pharmaceutical
to use only renewable electricity
in production. RE100 is a collaborative, global initiative of
businesses committed to using 100% renewable electricity.
Read more about Circular
for Zero and download
the full press release on the environmental ambitions
The International Committee of the Red Cross (ICRC), the Danish Red
Cross (DRC) and Novo Nordisk have partnered to tackle the growing
issue of chronic diseases that affect millions of people living in
humanitarian crises around the world. Focus will be on ensuring
efficient supply of low-cost human insulin in vials to Red Cross
globally; support for ICRC’s and DRC’s health programmes; 2-3 projects
to provide care to people with hypertension and diabetes in
humanitarian crises to be conducted within three years.
When Pâris was diagnosed with type 1 diabetes at the age of two, his mother Wendy began filming. She didn’t stop for 16 years.
1 November - third quarter
The Danish Government and Novo Nordisk have announced grants of 3 and 5 million US dollars respectively to the Defeat-NCD Partnership. The aim is to raise 100 million dollars to fund mobilisation of knowledge, tools, capacities and finances to scale-up action to defeat NCDs in low-resource countries.